Form 4 Filing for Naimish Patel

Naimish Patel, Chief Medical Officer at CRISPR Therapeutics AG, reported a series of transactions on March 14, 2026. Patel acquired 8,125 Common Shares through the vesting of Restricted Stock Units, with the shares remaining subject to a lock-up agreement. Concurrently, 8,125 Restricted Stock Units were granted, with vesting scheduled over four years starting March 14, 2026. On March 16, 2026, Patel disposed of 3,150 Common Shares at a price of $48.26 per share to cover tax withholding obligations related to the RSU vesting, as per the company's policy. Following these transactions, Patel holds 13,143 Common Shares.